Aoyanagi Eiko, Sasai Ken, Nodagashira Miho, Wang Lei, Nishihara Hiroshi, Ihara Hideyuki, Ikeda Yoshitaka, Tanaka Shinya
Laboratory of Cancer Research, Department of Pathology, Hokkaido University Graduate School of Medicine, N15 W7, Kita-ku, Sapporo, Japan.
Appl Immunohistochem Mol Morphol. 2010 Dec;18(6):518-25. doi: 10.1097/PAI.0b013e3181e3bf0d.
Glycosylation is one of the most common posttranslational modifications and changes in oligosaccharide structures are associated with many human diseases including a number of cancers. Thus, discovering aberrant glycosylation patterns that serve as markers for brain tumor progression and metastasis represents an attractive strategy to improve clinicopathologic diagnosis and to provide aids to the development of novel therapies. To identify glioblastoma (GBM) cells expressing glycoproteins that contain high levels of the bisecting N-acetylglucosamine (GlcNAc) structures, lectin histochemistry was carried out using erythroagglutinating phytohemagglutinin. Although GBM frequently expressed the bisecting GlcNAc, the lectin reactivity varied among tumor regions within individual specimens. Since detailed histopathologic analysis revealed that oligosaccharides with bisecting GlcNAc structures were preferably expressed in tumor regions with low KI67 immunopositivity, immunodetection of the bisecting GlcNAc could be useful to indicate less proliferative regions in human GBM. Our study highlights the potential use of lectin histochemistry to develop new methods for diagnosis that would improve future antiglioma therapy.
糖基化是最常见的翻译后修饰之一,寡糖结构的变化与包括多种癌症在内的许多人类疾病相关。因此,发现作为脑肿瘤进展和转移标志物的异常糖基化模式是一种有吸引力的策略,可用于改善临床病理诊断并为开发新疗法提供帮助。为了鉴定表达含有高水平平分型N-乙酰葡糖胺(GlcNAc)结构的糖蛋白的胶质母细胞瘤(GBM)细胞,使用红细胞凝集植物血凝素进行凝集素组织化学分析。尽管GBM经常表达平分型GlcNAc,但凝集素反应性在单个标本的肿瘤区域之间有所不同。由于详细的组织病理学分析显示,具有平分型GlcNAc结构的寡糖在KI67免疫阳性率低的肿瘤区域中优先表达,因此平分型GlcNAc的免疫检测可能有助于指示人类GBM中增殖较少的区域。我们的研究强调了凝集素组织化学在开发新诊断方法方面的潜在用途,这将改善未来的抗胶质瘤治疗。